Johnson & Johnson
JNJ
$253.04
+1.23%
Johnson & Johnson is the world's largest and most diversified healthcare company, operating through two primary segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). As a market leader in both drug development and medical technology, J&J's competitive identity is defined by its unparalleled scale, spanning immunology, oncology, and neurology, and its ability to cross-leverage scientific expertise across platforms. The current investor narrative centers on the company's post-Kenvue divestiture transformation, with a sharpened focus on high-growth pharmaceutical pipelines and margin expansion, while recent positive clinical trial data and strategic acquisitions (e.g., Firefly Bio) have bolstered sentiment around its long-term revenue growth trajectory.…
JNJ
Johnson & Johnson
$253.04
Related headlines
Investment Opinion: Should I buy JNJ Today?
Rating: Buy. Johnson & Johnson offers a compelling combination of accelerating revenue growth, expanding margins, and an attractive valuation, making it a strong candidate for long-term investors seeking quality healthcare exposure. The analyst consensus is Buy with an average target of $267.36, implying 8.2% upside. Supporting evidence: (1) Revenue grew 9.9% YoY in Q1 2026, accelerating from prior quarters; (2) Gross margin improved to 71.5% from 67.6% in Q4 2025; (3) Trailing P/E of 18.8x is a 15% discount to the industry average of 22x; (4) Free cash flow of $17.8B TTM supports a 2.46% dividend yield and strategic acquisitions. Risks: Litigation overhang, pipeline execution, and potential multiple compression if growth slows. This Buy rating would downgrade to Hold if revenue growth decelerates below 5% or if litigation costs materially impact earnings. Upgrade to Strong Buy if the stock pulls back to $220 or below, offering a wider margin of safety. Overall, JNJ appears undervalued relative to its history and peers, with a PEG ratio of 0.21 indicating the market is not fully pricing in its growth prospects.
Sign up to view all
JNJ 12-Month Price Forecast
Johnson & Johnson's strong operational momentum, with accelerating revenue and expanding margins, combined with a valuation discount to peers, supports a bullish stance. The PEG ratio of 0.21 suggests the market is not fully pricing in growth prospects, while the 2.46% dividend yield provides a floor. However, litigation overhang and near-term price proximity to the 52-week high temper confidence to medium. Key developments to watch include Q2 2026 earnings (due late July) for margin trends, IMAAVY regulatory updates, and any talc litigation resolutions. An upgrade to high confidence would require sustained revenue growth above 8% and a clear path to resolving legal liabilities.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Johnson & Johnson's 12-month outlook, with a consensus price target around $267.36 and implied upside of +5.7% versus the current price.
Average Target
$267.36
0 analysts
Implied Upside
+5.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$190 - $305
Analyst target range
Johnson & Johnson is covered by 22 analysts, with a consensus recommendation of 'Buy' (mean rating of 2.0 on a 1-5 scale, where 1 is Strong Buy). The average target price is $267.36, implying approximately 8.2% upside from the current price of $247.02. The distribution shows a bullish lean, with recent ratings from RBC Capital (Outperform), TD Cowen (Buy), Morgan Stanley (Overweight), and Citigroup (Buy) reinforcing positive sentiment. The target price range spans from a low of $190.00 to a high of $305.00. The high target of $305.00 assumes successful pipeline execution, margin expansion, and potential multiple expansion, while the low target of $190.00 factors in litigation risks, competitive pressures, or a broader market downturn. The spread of $115 (60% of the low target) indicates moderate uncertainty, but the concentration of recent upgrades (e.g., Leerink Partners upgraded from Market Perform to Outperform in May 2026) suggests growing conviction. Overall, the analyst community is optimistic about JNJ's prospects, with the average target offering a clear upside.
Drowning in data?
Find the real signal!
Bulls vs Bears: JNJ Investment Factors
Johnson & Johnson presents a compelling risk/reward profile with strong fundamental momentum—revenue accelerating to 9.9% YoY, expanding margins, and a trailing P/E of 18.8x that is a 15% discount to the industry average. The bull case is supported by robust free cash flow ($17.8B TTM), a healthy pipeline (IMAAVY, Firefly Bio), and analyst consensus Buy with 8.2% upside. However, the stock trades near its 52-week high, litigation overhang persists, and earnings growth expectations are modest. The single most important tension is whether the company can sustain its revenue acceleration and margin expansion to justify multiple expansion, or if litigation and competitive pressures will keep the stock range-bound. Currently, the bull case has stronger evidence given the valuation discount and operational improvements.
Bullish
- Strong Revenue Acceleration: Q1 2026 revenue grew 9.9% YoY to $24.06B, accelerating from 4.6% in Q4 2025 and 6.8% in Q3 2025, driven by Innovative Medicine (64% of sales) and positive pipeline momentum.
- Expanding Margins and Profitability: Gross margin improved to 71.5% in Q1 2026 from 67.6% in Q4 2025, and operating margin expanded to 26.6% from 22.8%, reflecting operational efficiencies and favorable product mix.
- Attractive Valuation vs. Peers: Trailing P/E of 18.8x is a 15% discount to the Drug Manufacturers industry average of ~22x, and the PEG ratio of 0.21 suggests undervaluation relative to growth.
- Strong Free Cash Flow Generation: TTM free cash flow of $17.8B provides ample liquidity for dividends (2.46% yield), acquisitions (e.g., Firefly Bio), and debt reduction, with a debt-to-equity ratio of 0.59.
Bearish
- Near 52-Week High, Limited Upside: At $247.02, the stock sits at 91.7% of its 52-week range ($159.80–$269.43), leaving only ~9% to the high, which may cap near-term gains.
- Litigation Overhang Remains: Ongoing talc-related lawsuits and other legal liabilities create uncertainty, potentially weighing on sentiment and valuation multiples.
- Modest Earnings Growth Expected: Forward P/E of 19.2x is slightly above trailing 18.8x, implying only modest earnings growth expectations, which may limit multiple expansion.
- Revenue Concentration in Pharma: Innovative Medicine accounts for 64% of revenue, making the company vulnerable to patent cliffs or pipeline failures in key therapeutic areas.
JNJ Technical Analysis
Johnson & Johnson is in a sustained uptrend, with the stock price up 59.2% over the past year, significantly outperforming the S&P 500's 20.9% gain. The current price of $247.02 sits at 91.7% of its 52-week range ($159.80–$269.43), indicating the stock is trading near the upper end of its range, reflecting strong momentum but also potential overextension. This positioning near highs suggests bullish sentiment is dominant, but investors should watch for resistance at the 52-week high. Over the past three months, JNJ has gained 5.3%, while the one-month return is 4.8%, showing accelerating short-term momentum. This recent strength aligns with the longer-term uptrend, with no divergence—the stock has been consistently climbing since mid-June 2026, when it broke above $240. The relative strength versus the S&P 500 over one month is +4.2%, confirming that JNJ is leading the market in the near term. The 52-week low of $159.80 provides strong support, while the 52-week high of $269.43 is the key resistance level. A breakout above $269.43 would signal a continuation of the uptrend and could open the door to further gains, while a breakdown below the recent support near $235 (the June 2026 consolidation area) would suggest a potential trend reversal. JNJ's beta is not provided, but given its defensive healthcare nature, it is likely below 1.0, meaning lower volatility than the market, which is favorable for risk-averse investors.
Beta
0.23
0.23x market volatility
Max Drawdown
-11.0%
Largest decline past year
52-Week Range
$163-$269
Price range past year
Annual Return
+55.3%
Cumulative gain past year
| Period | JNJ Return | S&P 500 |
|---|---|---|
| 1m | +8.0% | +0.3% |
| 3m | +8.1% | +4.7% |
| 6m | +15.7% | +7.5% |
| 1y | +55.3% | +18.4% |
| ytd | +22.0% | +9.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
JNJ Fundamental Analysis
Johnson & Johnson's revenue trajectory is solidly growing, with Q1 2026 revenue of $24.06 billion, up 9.9% year-over-year. This marks an acceleration from the 4.6% growth seen in Q4 2025 ($24.56 billion) and the 6.8% growth in Q3 2025 ($23.99 billion). The growth is driven by the Innovative Medicine segment, which contributed $15.43 billion in Q1 2026 (64% of total revenue), while MedTech added $8.64 billion. The strong pharmaceutical pipeline, including recent positive trial data for IMAAVY in rare blood disorders, supports continued growth. The company is highly profitable, with Q1 2026 net income of $5.24 billion and a net margin of 21.8%. Gross margin improved to 71.5% in Q1 2026 from 67.6% in Q4 2025, reflecting operational efficiencies and a favorable product mix. Operating margin also expanded to 26.6% from 22.8% over the same period, indicating strong cost control. The company's return on equity (ROE) stands at 32.9%, well above the pharmaceutical industry average, highlighting its ability to generate shareholder value. Johnson & Johnson maintains a strong balance sheet with a debt-to-equity ratio of 0.59, indicating moderate leverage. Free cash flow (FCF) for the trailing twelve months is $17.80 billion, providing ample liquidity for dividends, acquisitions, and debt repayment. The current ratio of 1.03 suggests adequate short-term liquidity. With a FCF yield of approximately 3.5% (FCF/market cap), the company generates sufficient cash to fund its operations and growth initiatives without relying heavily on external financing.
Quarterly Revenue
$24.1B
2026-03
Revenue YoY Growth
+9.9%
YoY Comparison
Gross Margin
71.5%
Latest Quarter
Free Cash Flow
$17.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is JNJ Overvalued?
Given Johnson & Johnson's positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is 18.8x, while the forward P/E is 19.2x, implying the market expects modest earnings growth. The slight premium in the forward multiple suggests investors are pricing in continued operational improvements and pipeline successes. Compared to the Drug Manufacturers - General industry average P/E of approximately 22x (based on sector data), JNJ trades at a 15% discount (18.8x vs. 22x), which is unusual for a market leader. This discount may reflect lingering concerns about litigation overhang or the post-Kenvue transition, but it also presents a potential value opportunity if the company delivers on its growth targets. Historically, JNJ's trailing P/E has ranged from roughly 9x (Q1 2025) to 36x (Q3 2024), with the current 18.8x near the lower end of its five-year band. This suggests the stock is not overvalued relative to its own history and may have room for multiple expansion if earnings growth accelerates. The PEG ratio of 0.21 (based on forward earnings growth) further supports the view that the stock is undervalued relative to its growth prospects.
PE
18.8x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 17x~36x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Johnson & Johnson's debt-to-equity ratio of 0.59 indicates moderate leverage, but the company's strong free cash flow of $17.8B TTM provides ample coverage. The net margin of 21.8% in Q1 2026 is healthy, though it was boosted by one-time items in prior quarters. Revenue concentration in Innovative Medicine (64%) exposes the company to patent expirations and pipeline failures. The PEG ratio of 0.21 suggests the market is pricing in low growth expectations, which could lead to multiple compression if growth disappoints. Market & Competitive Risks: The stock's trailing P/E of 18.8x is a discount to the industry average of 22x, but if the market re-rates the sector lower, JNJ could face valuation compression. Competitive threats from other large pharma companies and medtech innovators could pressure market share. Regulatory headwinds, such as drug pricing reforms, remain a risk. The stock's beta is likely below 1.0, providing some defense in market downturns, but a rotation out of healthcare could still impact the stock. Worst-Case Scenario: A combination of adverse litigation outcomes, pipeline setbacks (e.g., IMAAVY fails to gain approval), and a broad market downturn could drive the stock to its 52-week low of $159.80, representing a potential 35.3% decline from the current price of $247.02. This scenario would also involve multiple compression to the low end of its historical P/E range, around 12-14x.
FAQ
The key risks are: (1) Litigation overhang from talc-related lawsuits, which could result in significant settlements or verdicts; (2) Pipeline execution risk, as failure of key drugs like IMAAVY could slow growth; (3) Revenue concentration in Innovative Medicine (64% of sales), making the company vulnerable to patent cliffs; (4) Macro risks such as drug pricing reforms or a market downturn, though JNJ's low beta provides some defense. The most severe risk is a worst-case litigation scenario that could drive the stock down 35% to the 52-week low of $159.80.
The 12-month outlook is positive, with a base case target of $255-$275 (50% probability), aligning with the analyst average of $267.36. The bull case (25% probability) targets $280-$305, driven by strong pipeline execution and margin expansion, while the bear case (25% probability) targets $190-$220 if litigation or pipeline setbacks occur. The most likely scenario is the base case, assuming continued revenue growth of 6-8% and gradual margin improvement. The AI assessment is bullish with medium confidence, citing accelerating revenue, a valuation discount, and strong cash flows.
JNJ appears undervalued relative to its peers and its own history. The trailing P/E of 18.8x is below the Drug Manufacturers industry average of 22x, representing a 15% discount. Historically, JNJ's P/E has ranged from 9x to 36x over the past five years, and the current level is near the lower end of that range, suggesting room for multiple expansion. The PEG ratio of 0.21 indicates the stock is cheap relative to its earnings growth rate. The market is pricing in modest expectations, but with revenue accelerating to 9.9% YoY and margins expanding, the valuation does not fully reflect the company's improving fundamentals.
Yes, JNJ appears to be a good buy for long-term investors seeking a quality healthcare stock at a reasonable valuation. The trailing P/E of 18.8x is a 15% discount to the industry average of 22x, and the PEG ratio of 0.21 suggests the stock is undervalued relative to its growth prospects. Analyst consensus is Buy with an average target of $267.36, implying 8.2% upside. The biggest downside risk is litigation overhang, which could weigh on sentiment, but the company's strong free cash flow ($17.8B TTM) and accelerating revenue growth (9.9% YoY) provide a solid foundation. For risk-averse investors with a 3-5 year horizon, JNJ offers a compelling risk/reward profile.
JNJ is best suited for long-term investment, given its defensive nature, dividend growth (2.46% yield, 62-year increase streak), and moderate volatility (beta likely below 1.0). The stock's 59.2% gain over the past year shows strong momentum, but short-term traders may find limited upside near the 52-week high. A minimum holding period of 3-5 years is recommended to benefit from pipeline catalysts and compounding. For short-term investors, the stock's low beta and steady performance make it a less attractive trading vehicle compared to higher-beta names.
